Drug Trial Radar · NCT06237296
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
558
Actual
Start
Jan 23, 2024
Primary completion
Feb 11, 2025
Study completion Feb 11, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: * RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, * RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, * RSV mRNA / LNP 1 at 1 dose or, * hMPV mRNA / LNP 1 at 1 dose
Conditions
- Respiratory Syncytial Virus Infection
- Healthy Volunteers
- Metapneumovirus Infection
Interventions
RSV/hMPV mRNA LNP 1Biological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
RSV/hMPV mRNA LNP 2Biological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
RSV mRNA LNP 1Biological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
hMPV mRNA LNP 1Biological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of unsolicited systemic immediate adverse events (AEs)Time frame: Within 30 minutes after vaccination
- Presence of solicited injection site or systemic reactionsTime frame: Within 7 days after vaccination
- Presence of unsolicited AEsTime frame: Within 28 days after vaccination
- Presence of medically attended adverse events (MAAEs)Time frame: Throughout study (up to approximately 6 months)
- Presence of serious adverse events (SAEs)Time frame: Throughout study (up to approximately 6 months)
- Presence of adverse events of special interest (AESIs)Time frame: Throughout study (up to approximately 6 months)
- Presence of out-of-range biological test resultsTime frame: Within 7 days after vaccination
- RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent RSV formulationsTime frame: Day 1 and Day 29
- RSV-B serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent RSV formulationsTime frame: Day 1 and Day 29
- hMPV- A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- vaccination (D29) in the RSV/hMPV and monovalent hMPV formulationsTime frame: Day 1 and Day 29
Locations
17 sites in 2 countries. Site status is shown where the registry gives one.
Velocity Gardena Site Number : 8400011
Gardena, California
Velocity Clinical Research-Hallandale Beach- Site Number : 8400013
Hallandale, Florida
Advanced Clinical Research- Site Number : 8400005
Meridian, Idaho
Velocity Clinical Research, Sioux City Site Number : 8400017
Sioux City, Iowa
Velocity Clinical Research- New Orleans Site Number : 8400016
New Orleans, Louisiana
Meridian Clinical Research- Site Number : 8400007
Binghamton, New York
Velocity Clinical Research- Site Number : 8400012
Cleveland, Ohio
Coastal Carolina Research Center- Site Number : 8400001
North Charleston, South Carolina
Charlottesville Medical Research Center Winding River - Site Number : 8400002
Charlottesville, Virginia
Investigational Site Number : 0360007
Canberra, Australia
Investigational Site Number : 0360006
Blacktown, New South Wales, Australia
Investigational Site Number : 0360002
Botany, New South Wales, Australia
Investigational Site Number : 0360003
Kanwal, New South Wales, Australia
Investigational Site Number : 0360004
Sydney, New South Wales, Australia
Investigational Site Number : 0360008
Herston, Queensland, Australia
Investigational Site Number : 0360005
Morayfield, Queensland, Australia
Investigational Site Number : 0360001
Camberwell, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.